FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2057202551> ?p ?o ?g. }

• W2057202551 endingPage "1988" @default.
• W2057202551 startingPage "1979" @default.
• W2057202551 abstract "In a previous report, we described the results of a randomized, controlled trial that evaluated the potential of raloxifene to induce or exacerbate hot flushes. Here, we provide additional analyses that were undertaken to identify potential predictors of hot flushes and to assess the clinical usefulness of various therapeutic strategies for the reduction of hot flushes in postmenopausal women who receive raloxifene therapy.In this randomized, double-blind, placebo-controlled study, 487 unselected postmenopausal women were assigned randomly to receive treatment for 8 months with raloxifene, which was administered either at a dose of 60 mg/d every other day for 2 months followed by 60 mg/d (slow-dose escalation) or 60 mg/d throughout (raloxifene), or placebo. Data on the number, duration, intensity, and severity of hot flushes and awakenings because of night sweats were collected. Logistic regression models were used to examine the predictive value of various demographic and menopausal factors on the development or worsening of hot flushes.At baseline, 40.4% of all randomly assigned patients had hot flushes. The mean number of hot flushes (3-5 per week) was low. Fewer years postmenopause, surgical menopause, and previous estrogen or estrogen/progestin therapy were significant predictors of hot flushes at baseline but were not predictive of incident hot flushes during treatment with raloxifene. Of the women who received raloxifene therapy who had pre-existing hot flushes at baseline, 36% women had none at the end point. Early postmenopause and surgical menopause were significant predictors of a biologically relevant increase in hot flushes (>/=14 flushes/week). Early postmenopause, previous estrogen/progestin therapy, high body mass index, and greater duration of hot flushes at baseline were significant predictors of the need for symptomatic treatment. After 2 months of treatment, women in early postmenopause had significantly more hot flushes with raloxifene therapy than with slow-dose escalation ( P = .042), whereas there was no significant difference between raloxifene therapy and slow-dose escalation among women in later postmenopause. In the 50 patients who requested symptomatic treatment during the study, phytohormones or veralipride did not reduce the number of hot flushes markedly.A shorter time since menopause and surgical menopause are important predictors of hot flushes both before and during treatment with raloxifene. Previous estrogen/progestin therapy also increases the risk of hot flushes at baseline. For women in early postmenopause, slow-dose escalation of raloxifene therapy may be a suitable therapeutic strategy for the reduction of the risk of hot flushes." @default.
• W2057202551 created "2016-06-24" @default.
• W2057202551 creator A5013377152 @default.
• W2057202551 creator A5013462117 @default.
• W2057202551 creator A5014937507 @default.
• W2057202551 creator A5016392496 @default.
• W2057202551 creator A5020179668 @default.
• W2057202551 creator A5035778808 @default.
• W2057202551 creator A5051198567 @default.
• W2057202551 creator A5053149204 @default.
• W2057202551 creator A5077766982 @default.
• W2057202551 creator A5081305354 @default.
• W2057202551 creator A5081692327 @default.
• W2057202551 date "2004-12-01" @default.
• W2057202551 modified "2023-10-16" @default.
• W2057202551 title "Predictors of hot flushes in postmenopausal women who receive raloxifene therapy" @default.
• W2057202551 cites W1816167637 @default.
• W2057202551 cites W1972205502 @default.
• W2057202551 cites W1973757681 @default.
• W2057202551 cites W1983411928 @default.
• W2057202551 cites W1984078912 @default.
• W2057202551 cites W1986364825 @default.
• W2057202551 cites W1990844353 @default.
• W2057202551 cites W1995121929 @default.
• W2057202551 cites W1997883187 @default.
• W2057202551 cites W2004945195 @default.
• W2057202551 cites W2005733428 @default.
• W2057202551 cites W2006669125 @default.
• W2057202551 cites W2029872562 @default.
• W2057202551 cites W2037554945 @default.
• W2057202551 cites W2045471209 @default.
• W2057202551 cites W2061948111 @default.
• W2057202551 cites W2063285716 @default.
• W2057202551 cites W2064680992 @default.
• W2057202551 cites W2078303139 @default.
• W2057202551 cites W2084594676 @default.
• W2057202551 cites W2087724126 @default.
• W2057202551 cites W2092379290 @default.
• W2057202551 cites W2112629831 @default.
• W2057202551 cites W2124167012 @default.
• W2057202551 cites W2125591235 @default.
• W2057202551 cites W2145024831 @default.
• W2057202551 cites W2170750104 @default.
• W2057202551 cites W2172185687 @default.
• W2057202551 cites W4210958476 @default.
• W2057202551 doi "https://doi.org/10.1016/j.ajog.2004.04.042" @default.
• W2057202551 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15592280" @default.
• W2057202551 hasPublicationYear "2004" @default.
• W2057202551 type Work @default.
• W2057202551 sameAs 2057202551 @default.
• W2057202551 citedByCount "16" @default.
• W2057202551 countsByYear W20572025512012 @default.
• W2057202551 countsByYear W20572025512021 @default.
• W2057202551 countsByYear W20572025512022 @default.
• W2057202551 crossrefType "journal-article" @default.
• W2057202551 hasAuthorship W2057202551A5013377152 @default.
• W2057202551 hasAuthorship W2057202551A5013462117 @default.
• W2057202551 hasAuthorship W2057202551A5014937507 @default.
• W2057202551 hasAuthorship W2057202551A5016392496 @default.
• W2057202551 hasAuthorship W2057202551A5020179668 @default.
• W2057202551 hasAuthorship W2057202551A5035778808 @default.
• W2057202551 hasAuthorship W2057202551A5051198567 @default.
• W2057202551 hasAuthorship W2057202551A5053149204 @default.
• W2057202551 hasAuthorship W2057202551A5077766982 @default.
• W2057202551 hasAuthorship W2057202551A5081305354 @default.
• W2057202551 hasAuthorship W2057202551A5081692327 @default.
• W2057202551 hasConcept C121608353 @default.
• W2057202551 hasConcept C126322002 @default.
• W2057202551 hasConcept C142724271 @default.
• W2057202551 hasConcept C151956035 @default.
• W2057202551 hasConcept C168563851 @default.
• W2057202551 hasConcept C204787440 @default.
• W2057202551 hasConcept C27081682 @default.
• W2057202551 hasConcept C2777944059 @default.
• W2057202551 hasConcept C2778562196 @default.
• W2057202551 hasConcept C2779889926 @default.
• W2057202551 hasConcept C29456083 @default.
• W2057202551 hasConcept C530470458 @default.
• W2057202551 hasConcept C71924100 @default.
• W2057202551 hasConcept C84606932 @default.
• W2057202551 hasConceptScore W2057202551C121608353 @default.
• W2057202551 hasConceptScore W2057202551C126322002 @default.
• W2057202551 hasConceptScore W2057202551C142724271 @default.
• W2057202551 hasConceptScore W2057202551C151956035 @default.
• W2057202551 hasConceptScore W2057202551C168563851 @default.
• W2057202551 hasConceptScore W2057202551C204787440 @default.
• W2057202551 hasConceptScore W2057202551C27081682 @default.
• W2057202551 hasConceptScore W2057202551C2777944059 @default.
• W2057202551 hasConceptScore W2057202551C2778562196 @default.
• W2057202551 hasConceptScore W2057202551C2779889926 @default.
• W2057202551 hasConceptScore W2057202551C29456083 @default.
• W2057202551 hasConceptScore W2057202551C530470458 @default.
• W2057202551 hasConceptScore W2057202551C71924100 @default.
• W2057202551 hasConceptScore W2057202551C84606932 @default.
• W2057202551 hasIssue "6" @default.
• W2057202551 hasLocation W20572025511 @default.
• W2057202551 hasLocation W20572025512 @default.
• W2057202551 hasOpenAccess W2057202551 @default.

• next